Announcement PDF LTR Pharma Signs Collaborative Development Agreement to Develop a Novel Intranasal Spray for Oesophageal Motility Disorders (OMD) 08 May 2025 Highlights • • • • LTR Pharma enters into a collaborative development agreement with Strategic Drug Solutions, Inc. (SDS) Jointly developing OROFLOW®, a novel intranasal treatment for Oesophageal Motility Disorders (OMD) Designed for rapid symptom relief (~10 minutes) for patients with swallowing difficulties Targeting a $4.5 billion global market projected to reach $8.1 billion by 2034 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that it has entered into a collaborative development agreement with Strategic Drug Solutions, Inc (SDS) to co-develop OROFLOW®, a novel intranasal spray targeting Oesophageal Motility Disorders (OMD) – a group of conditions that cause impaired swallowing and impact quality of life for millions worldwide. This agreement builds on LTR Pharma’s foundational work and patent rights for SPONTAN® and ROXUS®, which LTR will now develop for OMD indications using its proprietary delivery platform and commercialisation capabilities. The program will commence towards Proof-of-Concept testing over the coming months and is targeted to provide prompt relief from discomfort and swallowing difficulties. Addressing a Significant Unmet Need OMD’s are a group of conditions characterised by abnormal contraction or relaxation of the oesophagus, leading to impaired swallowing (dysphagia) and related symptoms. Patients with OMD often struggle with swallowing both solids and liquids, and experience regurgitation, chest pain, and sometimes weight loss. Current treatments for OMD include invasive procedures such as pneumatic dilation, surgery, or botulinum toxin injections. There is a clear need for effective, non-invasive treatment options that can provide rapid relief for patients. LTR Pharma Executive Chairman, Lee Rodne, said: "OROFLOW represents an exciting expansion of our nasal spray platform. For patients with swallowing difficulties, oral medications present obvious challenges for patients. Our nasal spray technology is designed to offer a patient-friendly solution that avoids the need to swallow medications, have surgery or undergo other problematic treatments while providing rapid symptom relief. 1800 519 711 | ltrpharma.com | info@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569) The global prevalence of Oesophageal Motility Disorders has been increasing. We believe OROFLOW represents an important innovation that can significantly improve the quality of life for these patients. By addressing this specialised medical need with our proven nasal spray technology, we're pursuing a meaningful opportunity that aligns patient outcomes with long-term value creation." Market Opportunity The global market for treating OMD is substantial and growing. Current estimates value the global market for OMD treatment at $4.49 billion in 2024, with projections reaching $8.08 billion by 2034, representing a compound annual growth rate (CAGR) of 6.1%. The United States is the largest market at $1.94 billion, while significant opportunities exist in other regions, including East Asia, which accounts for approximately $326 million.1 This growth is driven by increasing prevalence, improvements in diagnostic capabilities, and expanding access to advanced treatments worldwide. Recent epidemiological studies published in United European Gastroenterology Journal (2024) indicate that the global prevalence of achalasia, which is a disorder that damages the nerves in the oesophagus, causing difficulties in swallowing, is approximately 10.82 cases per 100,000 persons, with regional variations showing higher rates in Australia (16.90 per 100,000), Europe (12.63 per 100,000), and North America (12.57 per 100,000).2 Recent clinical data from the United States estimate the incidence of dysphagia (difficulty swallowing) in adults over 50 years ranges from 16% to 22%.3 These figures highlight the substantial burden of OMDs in Western populations and underscore the need for innovative, non-invasive treatment options. The collaborative development agreement with SDS represents an important strategic milestone for LTR and strengthens its long-term partnership. It also marks LTR’s first entry into a new therapeutic indication, significantly expanding the Company’s product pipeline. While the financial impact of the agreement cannot be quantified at this stage, it reinforces LTRs growth strategy and potential future opportunities. There are no outstanding conditions required before the agreement takes full effect, and both parties are now legally committed to its terms. The Company is not aware of any additional information that would affect the price or value of its securities. References: 1. Fact.MR. "Ineffective Oesophageal Motility Treatment Market Analysis | 2034." Fact.MR, 2024. 2. Lee K, et al. Global trends in incidence and prevalence of achalasia, 1925-2021: A systematic review and meta-analysis. United European Gastroenterology Journal. 2024;12(2). 3. Oesophageal Motility Disorders. StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. - ENDS - This announcement has been approved by the Board of Directors. 1800 519 711 | ltrpharma.com | info@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569) About LTR Pharma LTR Pharma is an emerging pharmaceutical company committed to developing and commercialising innovative therapies that address significant unmet medical needs. The Company is leveraging its proprietary intranasal drug delivery platform to enable rapid, non-invasive treatment options across multiple therapeutic areas. LTR’s lead products, SPONTAN® and ROXUS®, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing OROFLOW®, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function. Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life. For further information please contact: Media enquiries Haley Chartres haley@hck.digital Investor enquiries Peter McLennan investors@ltrpharma.com 1800 519 711 | ltrpharma.com | info@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)